Partial inhibition of complex I activity increases Ca2+- independent glutamate release rates from depolarized synaptosomes

Journal of Neurochemistry

Volumn 106, Issue 2, 2008, Pages 826-834

  Kilbride, Seán M ^a   Telford, Jayne E ^a   Tipton, Keith F ^a   Davey, Gavin P ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Complex i; Glutamate release; Mitochondria; Neurodegeneration; Parkinson's disease; Synaptosomes

Indexed keywords

4 AMINOPYRIDINE; ADENOSINE TRIPHOSPHATE; CALCIUM ION; GLUTAMIC ACID; POTASSIUM CHLORIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; ANTIMETABOLITE; CALCIUM; DEOXYGLUCOSE;

ANIMAL CELL; ARTICLE; BRAIN SYNAPTOSOME; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ENZYME INHIBITION; EXCITOTOXICITY; FEMALE; INHIBITION KINETICS; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; METABOLISM; NERVE CELL; NERVE CELL INHIBITION; PHYSIOLOGY; SYNAPTOSOME; TIME; ULTRASTRUCTURE;

RATTUS;

ADENOSINE TRIPHOSPHATE; ANALYSIS OF VARIANCE; ANIMALS; ANTIMETABOLITES; BRAIN; CALCIUM; DEOXYGLUCOSE; ELECTRON TRANSPORT COMPLEX I; GLUTAMIC ACID; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEURAL INHIBITION; NEURONS; RATS; SYNAPTOSOMES; TIME FACTORS;

EID: 46349098565     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05441.x     Document Type: Article

References (60)

1. Allen K. L., Almeida A., Bates T. E. and Clark J. B. (1995) Changes of respiratory chain activity in mitochondrial and synaptosomal fractions isolated from the gerbil brain after graded ischaemia. J. Neurochem. 64, 2222-2229.
2. Almeida A., Allen K. L., Bates T. E. and Clark J. B. (1995) Effect of reperfusion following cerebral ischaemia on the activity of the mitochondrial respiratory chain in the gerbil brain. J. Neurochem. 65, 1698-1703.
3. Ashcroft S. J. and Ashcroft F. M. (1990) Properties and functions of ATP-sensitive K-channels. Cell. Signal. 2, 197-214.
4. Beal M. F. (1992a) Role of excitotoxicity in human neurological disease. Curr. Opin. Neurobiol. 2, 657-662.
5. Beal M. F. (1992b) Mechanisms of excitotoxicity in neurologic diseases. FASEB J. 6, 3338-3344.
6. Bergman H., Wichmann T., Karmon B. and DeLong M. R. (1994) The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 72, 507-520.
7. Bezard E., Boraud T., Bioulac B. and Gross C. E. (1997) Compensatory effects of glutamatergic inputs to the substantia nigra pars com- pacta in experimental parkinsonism. Neuroscience 81, 399-404.
8. Bonsi P., Calabresi P., De Persis C., Papa M., Centonze D., Bernardi G. and Pisani A. (2004) Early ionic and membrane potential changes caused by the pesticide rotenone in striatal cholinergic interneu- rons. Exp. Neurol. 185, 169-181.
9. Chinopoulos C., Tretter L. and Adam-Vizi V. (1999) Depolarization of in situ mitochondria due to hydrogen peroxide-induced oxidative stress in nerve terminals: inhibition of alpha-ketoglutarate dehydrogenase. J. Neurochem. 73, 220-228.
10. Davey G. P. and Clark J. B. (1996) Threshold effects and control of oxidative phosphorylation in nonsynaptic rat brain mitochondria. J. Neurochem. 66, 1617-1624.
11. Davey G. P., Canevari L. and Clark J. B. (1997) Threshold effects in synaptosomal and nonsynaptic mitochondria from hippocampal CA1 and paramedian neocortex brain regions. J. Neurochem. 69, 2564-2570.
12. Davey G. P., Peuchen S. and Clark J. B. (1998) Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J. Biol. Chem. 273, 12753-12757.
13. Dawson T. M. and Dawson V. L. (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822.
14. Doble A. (1999) The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 81, 163-221.
15. Erecinska M. (1987) The neurotransmitter amino acid transport systems. A fresh outlook on an old problem. Biochem. Pharmacol. 36, 3547-3555.
16. Erecinska M., Nelson D. and Silver I. A. (1996) Metabolic and energetic properties of isolated nerve ending particles (synaptosomes). Biochim. Biophys. Acta 1277, 13-34.
17. Greenamyre J. T., Sherer T. B., Betarbet R. and Panov A. V. (2001) Complex I and Parkinson's disease. IUBMB Life 52, 135-141.
18. Hornykiewicz O. and Kish S. J. (1987) Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45, 19-34.
19. Hossmann K. A. (2006) Pathophysiology and therapy of experimental stroke. Cell. Mol. Neurobiol. 26, 1057-1083.
20. Jiang C. and Haddad G. G. (1997) Modulation of K+ channels by intracellular ATP in human neocortical neurons. J. Neurophysiol. 77, 93-102.
21. +channel in substantia nigra neurons. J. Neurosci. 14, 5590-5602.
22. Kauppinen R. A. and Nicholls D. G. (1986a) Synaptosomal bioener- getics. The role of glycolysis, pyruvate oxidation and responses to hypoglycaemia. Eur. J. Biochem. 158, 159-165.
23. Kauppinen R. A. and Nicholls D. G. (1986b) Failure to maintain glycolysis in anoxic nerve terminals. J. Neurochem. 47, 1864-1869.
24. 2+concentration in isolated nerve terminals following metabolic inhibition: possible relevance to hypoglyca- emia and anoxia. Neuroscience 27, 175-182.
25. Keeney P. M., Xie J., Capaldi R. A. and Bennett Jr J. P. (2006) Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 26, 5256-5264.
26. Lai J. C. and Clark J. B. (1978) Isocitrate dehydrogenase and malate dehydrogenase in synaptic and non-synaptic rat brain mitochondria: a comparison of their kinetic constants. Biochem. Soc. Trans. 6, 993-995.
27. Lange K. W., Loschmann P. A., Sofic E., Burg M., Horowski R., Kal- veram K. T., Wachtel H. and Riederer P. (1993) The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn Schmiedebergs Arch. Pharmacol. 348, 586-592.
28. Lin M. T. and Beal M. F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795.
29. Mattson M. P. (2003) Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegen- erative disorders. Neuromolecular Med. 3, 65-94.
30. Mercuri N. B., Bonci A., Johnson S. W., Stratta F., Calabresi P. and Bernardi G. (1994) Effects of anoxia on rat midbrain dopamine neurons. J. Neurophysiol. 71, 1165-1173.
31. Mourre C., Ben Ari Y., Bernardi H., Fosset M. and Lazdunski M. (1989) Antidiabetic sulfonylureas: localization of binding sites in the brain and effects on the hyperpolarization induced by anoxia in hippo- campal slices. Brain Res. 486, 159-164.
32. Nicholls D. G. (1989) Release of glutamate, aspartate, and gamma- aminobutyric acid from isolated nerve terminals. J. Neurochem. 52, 331-341.
33. Nicholls D. G. (1993) The glutamatergic nerve terminal. Eur. J. Biochem. 212, 613-631.
34. Nicholls D. G. (2006) Simultaneous monitoring of ionophore- and inhibitor-mediated plasma and mitochondrial membrane potential changes in cultured neurons. J. Biol. Chem. 281, 14864-14874.
35. Nicholls D. G. and Budd S. L. (2000) Mitochondria and neuronal survival. Physiol. Rev. 80, 315-360.
36. Nicholls D. G. and Sihra T. S. (1986) Synaptosomes possess an exo- cytotic pool of glutamate. Nature 321, 772-773.
37. Nicholls D. G., Sihra T. S. and Sanchez-Prieto J. (1987) Calcium- dependent and -independent release of glutamate from synapto- somes monitored by continuous fluorometry. J. Neurochem. 49, 50-57.
38. Nieber K., Sevcik J. and Illes P. (1995) Hypoxic changes in rat locus coeruleus neurons in vitro. J. Physiol. 486, 33-46.
39. Obeso J. A., Rodriguez-Oroz M. C., Lanciego J. L. and Rodriguez Diaz M. (2004) How does Parkinson's disease begin? The role of compensatory mechanisms Trends Neurosci. 27, 125-127.
40. Parker Jr W. D. and Parks J. K. (2005) Mitochondrial ND5 mutations in idiopathic Parkinson's disease. Biochem. Biophys. Res. Commun. 326, 667-669.
41. Parker Jr W. D., Parks J. K. and Swerdlow R. H. (2008) Complex I deficiency in Parkinson's disease frontal cortex. Brain Res. 1189, 215-218.
42. 2/ glucose deprivation. J. Neurophysiol. 81, 2508-2516.
43. Ragan C. I., Wilson M. T., Darley-Uzmar V. M. and Lowe P. N. (1987) Mitochondria, a Practical Approach, pp. 77-112. IRL Press, London.
44. Reers M., Smith T. W. and Chen L. B. (1991) J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry 30, 4480-4486.
45. Reers M., Smiley S. T., Mottola-Hartshorn C., Chen A., Lin M. and Chen L. B. (1995) Mitochondrial membrane potential monitored by JC-1 dye. Methods Enzymol. 260, 406-417.
46. 2+-independent release of glutamate during in vitro anoxia in isolated nerve terminals. J. Neurochem. 57, 1159-1164.
47. 2+independent release of glutamate during anoxia in isolated nerve terminals (synaptosomes). J. Neurochem. 50, 13 -13 4.
48. Sanchez-Prieto J., Sihra T. S. and Nicholls D. G. (1987) Characterization of the exocytotic release of glutamate from guinea-pig cerebral cortical synaptosomes. J. Neurochem. 49, 58-64.
49. Santos M. S., Moreno A. J. and Carvalho A. P. (1996) Relationships between ATP depletion, membrane potential, and the release of neurotransmitters in rat nerve terminals. An in vitro study under conditions that mimic anoxia, hypoglycemia, and ischemia. Stroke 27, 941-950.
50. Schapira A. H., Cooper J. M., Dexter D., Jenner P., Clark J. B. and Marsden C. D. (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1 69.
51. Schapira A. H., Cooper J. M., Dexter D., Clark J. B., Jenner P. and Marsden C. D. (1990a) Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 8 3-8 7.
52. Schapira A. H., Mann V. M., Cooper J. M., Dexter D., Daniel S. E., Jenner P., Clark J. B. and Marsden C. D. (1990b) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55, 14 - 145.
53. Scott I. D. and Nicholls D. G. (1980) Energy transduction in intact synaptosomes. Influence of plasma-membrane depolarization on the respiration and membrane potential of internal mitochondria determined in situ. Biochem. J. 186, 1-33.
54. +) nigral tox- icity in the rat by prior decortication or MK-801 treatment: a stere- ological estimate of neuronal loss. Neurobiol. Aging 14, 295-301.
55. Storey E., Hyman B. T., Jenkins B., Brouillet E., Miller J. M., Rosen B. R. and Beal M. F. (1992) 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem. 58, 1975-1978.
56. +- channel inhibitors: an analysis of plasma membrane ion fluxes. J. Neurochem. 67, 389-397.
57. Tipton K. F. and Singer T. P. (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 1191-1206.
58. Tretter L., Sipos I. and Adam-Vizi V. (2004) Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease. Neurochem. Res. 29, 569-577.
59. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349, 414-418.
60. Zuddas A., Oberto G., Vaglini F., Fascetti F., Fornai F. and Corsini G. U. (1992) MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydro- pyridine-induced parkinsonism in primates. J. Neurochem. 59, 733-739.